The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The largest pharmacy-benefit managers hiked the prices of dozens of drugs dispensed through their own pharmacies, according to a new report by the Federal Trade Commission released on Tuesday.

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

WASHINGTON, Jan 14 (Reuters) - The nation's three largest pharmacy ... FTC spokesperson told reporters in a press briefing, adding that the figure was "probably an underestimate." Pharmacy benefit ...

After passing some regulations in 2024, Iowa state lawmakers are this year once again considering legislation that would ...

The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

US FTC Finds Major Pharmacy Benefit Managers Inflated Drug Prices for $7.3 Billion Gain By Ahmed Aboulenein and Amina Niasse WASHINGTON (Reuters) -The nation's three largest pharmacy benefit ...